安科生物(300009) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders increased by 24.58% to CNY 136,679,243.75 for the reporting period[3] - Operating revenue for the period was CNY 440,394,810.15, reflecting a year-on-year increase of 10.12%[3] - Basic earnings per share increased by 25.00% to CNY 0.10[3] - The company reported a decrease of 0.91% in revenue for the year-to-date period, totaling CNY 1,152,420,302.44[3] - Total operating revenue for Q3 2020 reached ¥440,394,810.15, an increase of 10.3% compared to ¥399,906,893.39 in the same period last year[27] - Net profit attributable to the parent company was ¥573,598,106.33, up from ¥465,819,501.94, reflecting a growth of 23.2% year-on-year[27] - The total profit for the quarter was CNY 160,222,615.62, compared to CNY 125,731,507.79 in the previous year, marking an increase of approximately 27.43%[30] - The total profit for the third quarter was CNY 351.22 million, compared to CNY 293.41 million in the previous year, marking an increase of 19.6%[35] Assets and Liabilities - Total assets increased by 3.55% to CNY 3,340,793,081.42 compared to the end of the previous year[3] - The company's net assets attributable to shareholders increased by 5.65% to CNY 2,775,205,460.57 compared to the end of the previous year[3] - The company's total liabilities decreased from approximately ¥526.19 million at the end of 2019 to approximately ¥483.91 million as of September 30, 2020[23] - The company's total liabilities were ¥407,501,320.13, an increase from ¥320,685,961.57, representing a rise of 27.1%[27] - Total assets as of September 30, 2020, amounted to CNY 3,226,206,230.51, with current assets totaling CNY 1,474,313,455.42[48] - Total liabilities were reported at CNY 526,185,936.42, with current liabilities amounting to CNY 414,435,773.13[49] - The company's equity attributable to shareholders was CNY 2,626,678,148.09, reflecting a solid capital base[50] Cash Flow - Net cash flow from operating activities rose by 33.38% to CNY 90,010,420.37[3] - Net cash flow from operating activities increased by 77.89% compared to the same period last year, driven by increased cash receipts from sales and reduced cash payments related to operating activities[12] - The company achieved a net cash inflow from operating activities of ¥270,096,640.59 for the year-to-date, compared to ¥127,991,976.94 in the same period last year, marking an increase of about 111.1%[45] - The ending balance of cash and cash equivalents was ¥57,733,966.82, down from ¥75,088,209.79 in the previous year, indicating a decrease of approximately 23.1%[42] - The company reported a total cash outflow from operating activities of ¥980,996,806.40, which is lower than ¥1,038,558,783.52 from the previous year, showing a reduction of about 5.5%[41] Investments and Expenses - Investment income for the first nine months of 2020 grew by 55.94% compared to the same period last year, mainly due to increased income from financial investments[11] - Other income for the first nine months of 2020 increased by 232.11% compared to the same period last year, primarily due to a significant increase in government subsidies recognized[11] - Research and development expenses for the quarter were ¥22,527,495.25, down from ¥24,424,859.80, a decrease of 7.8%[28] - Research and development expenses decreased to CNY 3,992,044.41 from CNY 14,572,345.49, a reduction of about 72.65%[31] - The company reported a decrease in financial expenses, with a net income of -¥1,161,738.35 compared to -¥4,305,223.81 in the previous year, indicating improved financial management[28] Shareholder Information - The total number of shareholders at the end of the reporting period was 79,240[5] - The company's share capital increased by 30% compared to the end of last year, following a capital reserve conversion decision made at the 2019 annual general meeting[11] - The company's employee stock ownership plan was approved, with a total of 8,879,060 shares issued, reflecting the company's commitment to employee engagement and retention[15] - The total number of participants in the second employee stock ownership plan has changed to 543 individuals[18] - The total shares held by the second employee stock ownership plan amount to 8,879,060 shares, representing 0.650% of the company's total share capital[17]